ES2176913T3 - Derivados de acidos arilsulfonilaminohidroxamicos. - Google Patents

Derivados de acidos arilsulfonilaminohidroxamicos.

Info

Publication number
ES2176913T3
ES2176913T3 ES98305959T ES98305959T ES2176913T3 ES 2176913 T3 ES2176913 T3 ES 2176913T3 ES 98305959 T ES98305959 T ES 98305959T ES 98305959 T ES98305959 T ES 98305959T ES 2176913 T3 ES2176913 T3 ES 2176913T3
Authority
ES
Spain
Prior art keywords
aryl
arilsulfonylaminohydroxamic
derivatives
acids
angiogenisis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98305959T
Other languages
English (en)
Inventor
Ralph Pelton Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2176913T3 publication Critical patent/ES2176913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

COMPUESTO DE FORMULA EN LA QUE AR ES (C 6 -C 10 )ARILO(C 6 C 10 )ARILO, UTIL EN EL TRATAMIENTO DE UNA P ATOLOGIA SELECCIONADA ENTRE EL GRUPO CONSISTENTE EN ARTRITIS, CANCER, ULCERACION TISULAR, REESTENOSIS, ENFERMEDAD PERIODONTAL, EPIDERMOLISIS BULLOSA, ESCLERITIS, OSTEORRESORCION, AFLOJAMIENTO DE IMPLANTE DE ARTICULACIONES ARTIFICIALES, ATEROSCLEROSIS, ESCLEROSIS MULTIPLE, ANGIOGENESIS OCULAR Y OTRAS ENFERMEDADES CARACTERIZADAS POR ACTIVIDAD DE LA METALOPROTEINASA MATRIZ, SIDA, SEPTICEMIA, CHOQUE SEPTICO Y OTRAS ENFERMEDADES QUE PRESENTAN LA PRODUCCION DE TNF.
ES98305959T 1997-08-08 1998-07-27 Derivados de acidos arilsulfonilaminohidroxamicos. Expired - Lifetime ES2176913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
ES2176913T3 true ES2176913T3 (es) 2002-12-01

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98305959T Expired - Lifetime ES2176913T3 (es) 1997-08-08 1998-07-27 Derivados de acidos arilsulfonilaminohidroxamicos.

Country Status (9)

Country Link
EP (1) EP0895988B1 (es)
JP (1) JPH11116549A (es)
AT (1) ATE217863T1 (es)
BR (1) BR9803128A (es)
CA (1) CA2244501C (es)
DE (1) DE69805473T2 (es)
DK (1) DK0895988T3 (es)
ES (1) ES2176913T3 (es)
PT (1) PT895988E (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
WO2000058280A1 (en) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
DK1041072T3 (da) * 1999-03-31 2003-11-10 Pfizer Prod Inc Dioxocyclopentylhydroxamsyrer
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
EP1208092B1 (en) * 2000-04-07 2006-06-21 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
ES2345977T3 (es) * 2001-03-14 2010-10-07 Novartis Ag Derivados de acido acetico azacicloalquil sustituidos para uso como inhibidores de mmp.
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
DE60231425D1 (de) * 2001-11-13 2009-04-16 Shiseido Co Ltd Azabicycloverbindung, matrixmetallproteaseinhibitor und zubereitung für haut
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7504537B2 (en) 2001-12-27 2009-03-17 Dainippon Sumitomo Pharma Co., Ltd. Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
CA2549660A1 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
KR20060109937A (ko) * 2003-12-15 2006-10-23 니뽄 다바코 산교 가부시키가이샤 Ｎ-치환-ｎ-술포닐아미노시클로프로판 화합물 및 그의약제학적 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ288299A (en) * 1994-06-22 1998-06-26 British Biotech Pharm Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PL331895A1 (en) * 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid

Also Published As

Publication number Publication date
EP0895988A1 (en) 1999-02-10
DE69805473T2 (de) 2003-01-16
PT895988E (pt) 2002-09-30
ATE217863T1 (de) 2002-06-15
DK0895988T3 (da) 2002-09-09
CA2244501A1 (en) 1999-02-08
DE69805473D1 (de) 2002-06-27
CA2244501C (en) 2003-03-18
EP0895988B1 (en) 2002-05-22
JPH11116549A (ja) 1999-04-27
BR9803128A (pt) 2000-05-02

Similar Documents

Publication Publication Date Title
BR9803128A (pt) Derivados de ácido arilsufonilamino-hidroxâmico
EP0818442A3 (en) Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
MY113586A (en) Aylsulfonylamino hydroxamic acid derivatives
CA2218503A1 (en) Arylsulfonyl hydroxamic acid derivatives
FR2744010B1 (fr) Procede de fabrication d'implants osseux
EA199900139A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
AP9801174A0 (en) Cyclic sulfone derivatives.
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
GB9716656D0 (en) Chemical compounds
FR2735351B1 (fr) Implant pour le traitement chirurgical d'une fracture isthmique vertebrale
YU37499A (sh) Derivati arilsulfonil hidroksamske kiseline
WO2003007719A1 (fr) Nettoyants, systeme de nettoyage, agents de blanchiment et compositions pour la preservation de l'environnement
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
NO20010490D0 (no) Inhibisjon av ''graft-versus-host''-sykdom
PT900211E (pt) Tiadiazolil(tio)ureias uteis como inibidores de metaloproteases com matriz
CA2340138A1 (en) 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
CA2217051A1 (en) Epoxysuccinic acid derivatives
WO2000015208A3 (en) New use of immunosupressants for mmp-mediated diseases
CA2253796A1 (en) Inhibition of matrix metalloproteases by acetylene containing compounds
IT1291511B1 (it) Estensore di catena per la sintesi di polimeri biocompatibili eparinizzabili
CA2397960A1 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
EP0822260A4 (en) SUBSTANCE FA-70D, MANUFACTURING METHOD AND USE
TR200003877T2 (tr) İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri